← 返回

维生素 B6 维持 CD8(+) T 细胞的干性样表型和抗肿瘤能力

英文原题:Vitamin B6 preserves the stemness-like phenotypes and antitumor ability of CD8(+) T cells.

查看英文原题

Vitamin B6 preserves the stemness-like phenotypes and antitumor ability of CD8(+) T cells.

PubMed 2025/11/27(内容时间) Dev Cell Q1 · IF 9.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

TIL(肿瘤浸润淋巴细胞)通常功能失调,但表现出干细胞样行为,其机制尚不清楚。在此,我们报道给予维生素B6或其活性形式磷酸吡哆醛(PLP)可使小鼠和人类CD8+ T细胞具有改善的持久性、干细胞样表型和肿瘤清除能力。通过吡哆醛激酶(PDXK)杂合性降低PLP会导致肿瘤中T细胞干细胞样特性减少和耗竭表型增加。在机制上,PLP通过直接结合并抑制p70S6激酶(p70S6K)来维持T细胞功能。通过限制p70S6K介导的BTB结构域和CNC同源物2(BACH2)磷酸化,PLP增加BACH2的核滞留和功能激活,促进干细胞基因表达,同时抑制耗竭基因表达。在临床前肿瘤模型中,PLP治疗提高了抗程序性死亡受体1(PD-1)抗体疗法的疗效。因此,我们的研究揭示了一条保留T细胞功能性干细胞样表型以驱动抗肿瘤免疫获得的通路,突显了维生素B6/PLP增强T细胞功能策略在癌症免疫治疗中的临床潜力。

展开英文摘要原文

Tumor-infiltrating lymphocytes are usually dysfunctional but demonstrate stem cell-like behavior through unclear mechanisms.

Here, we report that administration of vitamin B6 or its active form, pyridoxal phosphate (PLP), endows mouse and human CD8 + T cells with improved persistence, stemness-like phenotypes, and tumor clearance capabilities. Lowering PLP by pyridoxal kinase (PDXK) heterozygosity results in reduced T cell stemness-like properties and increased exhaustion phenotypes in tumors.

Mechanistically, PLP preserves T cell function by directly binding to and inhibiting p70S6 kinase (p70S6K). Through limiting p70S6K-mediated BTB domain and CNC homolog 2 (BACH2) phosphorylation, PLP increases nuclear retention and functional activation of BACH2, promoting stemness gene expression while dampening exhaustion gene expression. In preclinical tumor models, PLP treatment improves the efficacy of anti-programmed death receptor 1 (PD-1) antibody therapy.

Thus, our study reveals a pathway that preserves T cell functional stemness-like phenotypes to drive the acquisition of antitumor immunity, highlighting the clinical potential of vitamin B6/PLP-enhanced T cell function strategies in cancer immunotherapy.

论文信息

作者
Wu J、Li G、Zhou J、Sun X、Wang H、Gong H、Jiang P
第一作者单位
State Key Laboratory of Molecular Oncology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China; School of Pharmaceutical Sciences, The First Affiliated Hospital, State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, Fujian 361102, China; Shenzhen Research Institute of Xiamen University, Shenzhen, Guangdong 518057, China.China
通讯作者单位
State Key Laboratory of Molecular Oncology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China. Electronic address: pengjiang@tsinghua.edu.cn.China
期刊
Developmental cell2026 Mar 11
原文标识
PubMed 41314217 · DOI 10.1016/j.devcel.2025.10.017